0001104659-16-131409.txt : 20160707 0001104659-16-131409.hdr.sgml : 20160707 20160707060233 ACCESSION NUMBER: 0001104659-16-131409 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20160706 FILED AS OF DATE: 20160707 DATE AS OF CHANGE: 20160707 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Syros Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001556263 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 453772460 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 480 ARSENAL STREET STREET 2: SUITE 130 CITY: WATERTOWN STATE: MA ZIP: 02472 BUSINESS PHONE: 617-744-1340 MAIL ADDRESS: STREET 1: 480 ARSENAL STREET STREET 2: SUITE 130 CITY: WATERTOWN STATE: MA ZIP: 02472 FORMER COMPANY: FORMER CONFORMED NAME: LS22, Inc. DATE OF NAME CHANGE: 20120815 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: BYBEE CLINTON CENTRAL INDEX KEY: 0001219043 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37813 FILM NUMBER: 161755483 MAIL ADDRESS: STREET 1: 8755 W. HIGGINS ROAD STREET 2: SUITE 1025 CITY: CHICAGO STATE: IL ZIP: 60631 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: CRANDELL KEITH CENTRAL INDEX KEY: 0001219039 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37813 FILM NUMBER: 161755484 MAIL ADDRESS: STREET 1: 8755 W. HIGGINS ROAD STREET 2: SUITE 1025 CITY: CHICAGO STATE: IL ZIP: 60631 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: ARCH Venture Partners VII, LLC CENTRAL INDEX KEY: 0001544443 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37813 FILM NUMBER: 161755485 BUSINESS ADDRESS: STREET 1: 8755 W. HIGGINS ROAD STREET 2: SUITE 1025 CITY: CHICAGO STATE: IL ZIP: 60631 BUSINESS PHONE: 773-380-6600 MAIL ADDRESS: STREET 1: 8755 W. HIGGINS ROAD STREET 2: SUITE 1025 CITY: CHICAGO STATE: IL ZIP: 60631 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: ARCH Venture Partners VII, L.P. CENTRAL INDEX KEY: 0001544444 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37813 FILM NUMBER: 161755486 BUSINESS ADDRESS: STREET 1: 8755 W. HIGGINS ROAD STREET 2: SUITE 1025 CITY: CHICAGO STATE: IL ZIP: 60631 BUSINESS PHONE: 773-380-6600 MAIL ADDRESS: STREET 1: 8755 W. HIGGINS ROAD STREET 2: SUITE 1025 CITY: CHICAGO STATE: IL ZIP: 60631 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Arch Venture Fund VII LP CENTRAL INDEX KEY: 0001402439 STATE OF INCORPORATION: DE FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37813 FILM NUMBER: 161755487 BUSINESS ADDRESS: STREET 1: 8755 W HIGGINS STREET 2: SUITE 1025 CITY: Chicago STATE: IL ZIP: 60631 BUSINESS PHONE: 773-380-6600 MAIL ADDRESS: STREET 1: 8755 W HIGGINS STREET 2: SUITE 1025 CITY: Chicago STATE: IL ZIP: 60631 4 1 a4.xml 4 X0306 4 2016-07-06 0 0001556263 Syros Pharmaceuticals, Inc. SYRS 0001402439 Arch Venture Fund VII LP 8755 WEST HIGGINS ROAD, SUITE 1025 CHICAGO IL 60631 0 0 1 0 0001544444 ARCH Venture Partners VII, L.P. 8755 WEST HIGGINS ROAD, SUITE 1025 CHICAGO IL 60631 0 0 1 0 0001544443 ARCH Venture Partners VII, LLC 8755 WEST HIGGINS ROAD, SUITE 1025 CHICAGO IL 60631 0 0 1 0 0001219039 CRANDELL KEITH 8755 WEST HIGGINS ROAD, SUITE 1025 CHICAGO IL 60631 0 0 1 0 0001219043 BYBEE CLINTON 8755 WEST HIGGINS ROAD, SUITE 1025 CHICAGO IL 60631 0 0 1 0 Common Stock 2016-07-06 4 C 0 266666 A 479999 D Common Stock 2016-07-06 4 C 0 1333333 A 1813332 D Common Stock 2016-07-06 4 C 0 2000000 A 3813332 D Common Stock 2016-07-06 4 C 0 423805 A 4237137 D Common Stock 2016-07-06 4 P 0 400000 12.50 A 4637137 D Series A-1 Preferred Stock 2016-07-06 4 C 0 1000000 0 D Common Stock 266666 0 D Series A-2 Preferred Stock 2016-07-06 4 C 0 5000000 0 D Common Stock 1333333 0 D Series A-3 Preferred Stock 2016-07-06 4 C 0 7500000 0 D Common Stock 2000000 0 D Series B Preferred Stock 2016-07-06 4 C 0 1589269 0 D Common Stock 423805 0 D The Series A-1 Preferred Stock converted into Common Stock on a 3.75-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-1 Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. The Series A-2 Preferred Stock converted into Common Stock on a 3.75-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-2 Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. The Series A-3 Preferred Stock converted into Common Stock on a 3.75-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-3 Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. The Series B Preferred Stock converted into Common Stock on a 3.75-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. These shares are owned directly by ARCH Venture Fund VII, L.P. ("ARCH Fund VII"). The sole general partner of ARCH Fund VII is ARCH Venture Partners VII, L.P. ("ARCH Partners VII"). The sole general partner of ARCH Partners VII is ARCH Venture Partners VII, LLC ("ARCH VII LLC"). The Managing Directors of ARCH VII LLC, Robert T. Nelsen, Keith Crandell and Clinton Bybee, are deemed to have voting and dispositive power over the shares and may be deemed to beneficially own certain shares held by ARCH Fund VII. Each Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Persons are the beneficial owners of such securities for Section 16 or any other purpose. ARCH Venture Fund VII, L.P. By: ARCH Venture Partners VII, L.P. By: /s/Mark McDonnell, as Attorney-in-Fact for Keith Crandell, the Mgng Dir of ARCH VII LLC, the GP of ARCH Partners VII, the GP of ARCH Fund VII Name: Mark McDonnell Title: Attorney-in fact 2016-07-06 ARCH Venture Partners VII, L.P. By: ARCH Venture Partners VII, LLC By: /s/ Mark McDonnell as Attorney-in-Fact for Keith Crandell, the Managing Director of ARCH VII LLC, the general partner of ARCH Partners VII Name: Mark McDonnell Title: Attorney-in fact 2016-07-06 ARCH Venture Partners VII, LLC By: /s/ Mark McDonnell as Attorney-in-Fact for Keith Crandell, the Managing Director of ARCH VII LLC Name: Mark McDonnell Title: Attorney-in fact 2016-07-06 /s/ Mark McDonnell, as Attorney-in-Fact for Keith Crandell Keith Crandell 2016-07-06 /s/ Mark McDonnell, as Attorney-in-Fact for Clinton Bybee 2016-07-06